Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Clinical trial NCT00504959 · COMPLETED

Trial details

NCT number: NCT00504959
Sponsor: Novartis
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Subfoveal Choroidal Neovascularization (CNV)Secondary to Age-related Macular Degeneration (AMD)

Start date: 2007-07-01
Primary completion: 2010-01-01
Enrollment: 234

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.